Press Releases

Date Title
Toggle Summary Kura Oncology Announces Launch of Public Offering of Common Stock
LA JOLLA, Calif. , Oct. 28, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced that it has commenced an underwritten public offering of
Toggle Summary Kura Oncology Appoints Thomas Malley to Board of Directors
LA JOLLA, Calif. , Oct. 14, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of directors. "Tom has extensive knowledge and understanding of the healthcare industry," said Troy Wilson
Toggle Summary Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
Second of Two Planned Company Sponsored Phase 2 Trials for Tipifarnib LA JOLLA, Calif. , Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers,
Toggle Summary Kura Oncology Cleared for Quotation on the OTCQB
LA JOLLA, Calif. , Sept. 16, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced today that its common stock has been approved for quotation
Toggle Summary Kura Oncology to Present at the 2015 Wedbush PacGrow Healthcare Conference
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the 2015 Wedbush PacGrow Healthcare Conference.
Toggle Summary Kura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
LA JOLLA, Calif. , May 27, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. , a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the Jefferies 2015 Global Healthcare Conference.
Toggle Summary Kura Oncology First Patient Dosed in Phase 2 Study of Tipifarnib in Advanced Cancers with HRAS Mutations
First of Two Planned Phase 2 Studies of Tipifarnib LA JOLLA, May 18, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced that the first
Toggle Summary Faheem Hasnain joins Kura Oncology's Board of Directors
LA JOLLA, April 27, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced the appointment of Faheem Hasnain to the Company’s board of
Toggle Summary Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan
LA JOLLA, March 30, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by University of Michigan researchers in the
Toggle Summary Kura Oncology Announces License Agreement with Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger
LA JOLLA, March 12, 2015 – Kura Oncology, Inc. (“Kura Oncology” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milestones.